Publicaciones en las que colabora con ROSA MARÍA AYALA DÍAZ (76)

2024

  1. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges

    Frontiers in Immunology, Vol. 15

  2. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  3. Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience

    Cancers, Vol. 16, Núm. 18

  4. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

  2. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  3. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  4. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

    Life, Vol. 13, Núm. 9

  5. Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma (Journal of Hematology & Oncology, (2023), 16, 1, (76), 10.1186/s13045-023-01474-w)

    Journal of Hematology and Oncology

  6. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

    Frontiers in immunology

  7. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients (Frontiers in Immunology, (2023), 14, (1188818), 10.3389/fimmu.2023.1188818)

    Frontiers in Immunology

  8. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma

    Journal of Hematology and Oncology

  9. Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

    Frontiers in Pharmacology, Vol. 14

  10. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

    Leukemia, Vol. 37, Núm. 8, pp. 1649-1659

  11. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

    Leukemia, Vol. 37, Núm. 3, pp. 659-669

  12. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  2. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  3. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  4. No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

    Disease markers, Vol. 2022, pp. 3132941